A b s t r a c t
The c-mos gene and its protein product mos, components of the mitogen-activated protein kinase transduction pathway, are known to be involved in the control of meiosis and mitosis. Apart from our previous studies on lung carcinomas and astrocytic gliomas, little has been published about its role in human neoplasia. The aim of this study was to investigate the expression of mos in ependymal neoplasms and to correlate it with tumor grade, proliferative fraction, and clinical behavior.
We studied mos expression in biopsy specimens from 34 
patients with ependymomas. Intracytoplasmic immunopositivity for mos was found in 16 (47%) and was associated significantly with tumor grade: 5 (24%) of 21 grade II ependymomas; 11 (85%) of 13 grade III anaplastic ependymomas (P < .01). Tumors with an MIB-1 labeling index of more than 4% were significantly more likely than those with a lower proliferative fraction to be immunopositive for mos (P = .012). Expression of mos showed a significant negative association with recurrence-free interval (P = .05) but not with overall survival. Our results suggest that overexpression of mos identifies a biologically aggressive subgroup of ependymal tumors and may be involved in their neoplastic progression.
c-mos, the proto-oncogene located in humans on chromosome 8q11-12, encodes mos, a 39-kd protein that is a component of the mitogen-activated protein kinase (MAPK) transduction pathway. 1 Much of the research to date on mos has concerned its role in meiosis. Its functions as a regulator of meiotic maturation, essential for meiosis I and meiosis II, have been the subject of several comprehensive reviews. [1] [2] [3] mos or its coding messenger RNA have been demonstrated at low levels in most somatic tissues. [4] [5] [6] High levels of mos were reported to cause somatic cell death, 7 which probably results from p53-mediated growth arrest and apoptosis. 8 In addition, increased expression of c-mos has been linked to neoplastic transformation of some somatic cells. 9 Our understanding of this proneoplastic action is still incomplete. It has been suggested that overexpression of c-mos may cause cells to acquire a meiosis-like phenotype, with compromise of the mitotic checkpoints that normally ensure integrity of genetic material and symmetry of cell division during mitosis. 8, 10, 11 An alternative proposal is that altered MAPK activity resulting from overexpression of c-mos interferes with normal cyclin D1-Cdk4-pRb-E2F signaling. 1, 12, 13 Loss of p53 cell checkpoint activity is thought to be one of the permissive events in this process. 8 Athanasiou et al 14 and Gorgoulis et al 15 showed increased transcription of c-mos and elevated levels of immunostainable mos in a high proportion of human lung carcinomas. More recently, Perunovic et al 16 found a significant correlation between the expression of mos and the grade of astrocytic glioma. The present study concerns the expression of mos in ependymomas.
From a molecular genetic and a histologic perspective, ependymomas are distinct from astrocytic tumors. 17 Consistent alterations of the major cellular regulatory pathways that have been reported in astrocytic tumors, such as mutations of EGFR, PTEN, and p16 CDKN2a , have not been observed in most ependymomas. [18] [19] [20] [21] [22] [23] Furthermore, histologic features are less reliable predictors of the biologic behavior of ependymal than of astrocytic gliomas. 17 Our aim was to study the expression of mos in ependymal tumors of different histologic grades and to correlate expression with the recurrence-free interval and total survival. In addition, because the proliferative fraction of the tumor, as determined by immunohistochemical analysis with MIB-1 antibody to Ki-67, has been shown to correlate inversely with survival in patients with ependymoma, 24, 25 we were interested to find out whether the expression of mos correlated with the MIB-1 labeling index (MIB-1 LI) in this type of tumor.
Materials and Methods

Cases Studied
We studied ependymal tumors from 34 patients whose biopsy specimens were examined in the Department of Neuropathology, Frenchay Hospital, Bristol, England, between January 1988 and August 2000. The study was approved by the Frenchay Hospital Research Ethics Committee. Twenty of the patients were males (59%) and 14 females (41%). The age at diagnosis ranged from 6 months to 76 years (mean, 23.3 years; SD, 22.5 years). The original slides were reviewed, and the grading according to World Health Organization (WHO) criteria 17 was confirmed in all cases. Twenty-one were ependymomas of WHO grade II, and 13 were anaplastic ependymomas (WHO grade III). In 18 cases (53%), the neoplasm was in the posterior fossa, and in 11 (32%), it was in the supratentorial compartment. The remaining 5 cases (15%) had grade II spinal ependymomas of typical type. Subependymoma, myxopapillary ependymoma, and other variants of ependymoma were not included in the study. Relevant clinical and follow-up data were obtained by examining the patients' hospital and outpatient records, by contacting the patients' general practitioners, and, when necessary, by inquiry to the local health authority.
Immunohistochemical Analysis
Immunocytochemistry was performed on 5-µm-thick sections cut from the paraffin blocks originally used for diagnostic purposes. Sections were dewaxed and rehydrated and then immersed for 30 minutes in methanol containing 0.9% hydrogen peroxide. Antigen retrieval was performed by microwaving the sections in a 0.01-mol/L concentration of sodium citrate buffer (pH 6.0); the buffer twice was brought to the boiling point over a 5-minute period. The sections were incubated overnight at room temperature in anti-c-mos (P-19) goat polyclonal antiserum (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:400 or mouse monoclonal antibody to Ki-67 (MIB-1, DAKO, Cambridge, England) diluted 1:4,000. Bound antibody was visualized by incubation with biotinylated secondary antibody, either Vectastain Universal Elite or Goat Vectastain Elite (Vector Laboratories, Peterborough, England) as appropriate, then avidin-biotin horseradish peroxidase, and reaction with a 0.01% solution of hydrogen peroxide and diaminobenzidine.
Three lung carcinoma specimens previously shown to express mos 14 were used as positive control specimens for mos immunostaining and a standard laboratory control (anaplastic astrocytoma) as a positive control for MIB-1. Negative controls comprised sections immunostained as described in the preceding paragraph, apart from the omission of the primary antibody. The staining was assessed by first surveying the entire section under a 10× objective and then counting labeled cells by examination of 500 tumor cells under a 40× objective in the area where the density of labeled cells was greatest. Staining for mos was cytoplasmic and for Ki-67, nuclear. A positive result was defined as the staining of more than 10% of the tumor cells for mos 16 and more than 4% of the tumor cells for Ki-67. 25 
Statistical Analysis
We assessed the expression of mos in relation to sex, age, tumor grade, and MIB-1 labeling. The data were analyzed using the Pearson χ 2 test with Yates correction or the Fisher exact test when appropriate. 26, 27 Thirty-three cases with follow-up data were subjected to Kaplan-Meier survival analysis. For comparisons of survival in different populations, the log-rank test was used. Disease-related survival was defined as the interval between the date of the surgery and the date of death due to tumor, while recurrence-free survival was defined as the interval between the date of surgery and the date of clinical manifestations of recurrence. SPSS for Windows R10 software (SPSS, Chicago, IL) was used for statistical calculations. Probability values of less than .05 were considered significant.
Results
Clinical Follow-up
In all cases, the initial surgery was described as having achieved complete or almost complete macroscopic resection of the tumor. Twenty-two patients (65%), 10 of whom had grade II tumors and 12 grade III, received additional treatment: radiotherapy only (6 patients), chemotherapy only (6 patients), radiotherapy in combination with chemotherapy (6 patients), radiotherapy followed by further surgery (2 patients), chemotherapy followed by further surgery (1 patient), or a combination of radiotherapy and chemotherapy followed by further surgery (1 patient). Most patients who received multiple modes of additional treatment had anaplastic ependymoma. For one of two patients with grade II ependymoma, the additional treatment was radiotherapy followed by further surgery, and for the second, radiotherapy and chemotherapy. In the patient with a grade II tumor on whom further surgery was performed, histologic examination of the second biopsy specimen revealed higher grade (anaplastic) tumor than had been present initially.
One patient with a grade II tumor was lost to follow-up. At the time of data analysis, 15 patients (44%) had died. They were followed up for a median duration of 36.3 months (range, 10.2-118.7 months; mean, 45 months; SD, 29 months). The remaining 18 patients had been followed up for a median duration of 53 months (mean, 67 months; SD, 49 months). The median survival was 44.5 months (mean, 57 months; SD, 42 months) for the entire cohort. Clinical data are summarized in ❚Table 1❚.
Immunohistochemical Findings
Immunohistochemical expression of mos was found in 16 of (47%) 34 cases. The proportion of the positive cases varied with tumor grade: 5 (24%) of 21 grade II ependymomas and 11 (85%) of 13 anaplastic ependymomas. Of 5 spinal grade II ependymomas, 1 showed expression of mos.
In most cases, staining had a distinct, punctuate pattern, with single or multiple small cytoplasmic inclusions, standing out clearly against the immunonegative surrounding cytoplasm ❚Image 1❚. Only occasional weak membranous or nuclear staining was seen and was disregarded for the purposes of scoring. In most cases, the expression of mos was patchy, and the density of positive cells varied in different parts of the tumor.
Immunolabeling was confined to the tumor cells. Astrocytes in adjacent brain tissue, endothelium, inflammatory cells, and neurons were completely lacking in detectable mos.
In 13 cases (38%), the MIB-1 LI was 4% or more, and in 21 cases (62%), the MIB-1 LI was less than 4%. In relation to the tumor grade, 2 (10%) of 21 grade II ependymomas and 11 (85%) of 13 grade III anaplastic tumors showed an MIB-1 LI of 4% or more. The MIB-1 LIs in 19 grade II ependymomas were between 0.1% and 2% (mean, 0.4%; median, 0.1%). The remaining 2 grade II ependymomas showed MIB-1 LIs of 5% and 11%. Eleven grade III tumors showed MIB-1 LIs between 10% and 50% (mean, 24%; median, 18%). The remaining 2 grade III ependymomas showed MIB-1 LIs of 0.1% and 1%.
In many areas of the same mos-positive tumor, strong immunostaining for mos was found where the MIB-1 LI was more than 4%. However, MIB-1 staining tended to be relatively homogeneous throughout individual tumors, whereas mos staining was patchy.
Relationship Between mos and Clinicopathologic Features
Immunopositivity for mos was significantly more frequent in higher-grade ependymal tumors (P < .01), both in relation to the whole series and when the 5 cases of spinal ependymoma were omitted from the analysis (P < .001 and P = .003, respectively). Immunopositivity for mos was also associated significantly with MIB-1 labeling of more than 4% of the tumor cells (P = .012 and P = .025, respectively), but no linear relation between these 2 variables was noted. Statistical data are summarized in ❚Table 2❚. As illustrated in the survival plots ❚Figure 1❚, immunopositivity for mos showed a significant negative association with recurrence-free interval (log rank = 3.55; P = .05) but not with overall survival (log rank = 1.27; P = .27). There was no significant association between the presence of detectable mos and the sex or age of the patients.
Discussion
To the best of our knowledge, no previous studies have examined the expression of mos in ependymal tumors. Apart from previous studies of astrocytic neoplasms by Perunovic et al 16 and of lung carcinomas by Athanasiou et al, 14 Gorgoulis et al, 15 and Zacharatos et al, 28 review of the literature revealed only 5 studies of c-mos in human tumors. Low levels of c-mos expression were detected in vitro in human cervical carcinoma-derived cell lines. 6 Elevated levels of cmos messenger RNA were demonstrated in 1 case of medullary carcinoma of the thyroid 29 and in 3 carcinomas and 1 germ cell tumor of the ovary. 30 Mutations of c-mos were detected in 2 of 23 pleomorphic adenomas of the salivary gland 31 but not in ovarian teratomas. 32 In the present study, almost half of the ependymal tumors were immunopositive for mos. The proportion of positive cases was significantly higher in the tumors with histologic features of more aggressive behavior, as assessed by conventional morphologic evaluation (ie, fulfilling the criteria for a diagnosis of WHO grade III anaplastic ependymoma) or by determination of the proliferative fraction, with MIB-1. As previously documented for astrocytic tumors 16 and non-small cell carcinomas of the lung, 14 there was considerable heterogeneity in mos expression in different parts of the same tumor, probably reflecting clonal diversity rather than variation related to the stage in the cell cycle. 3, 6 Perunovic et al 16 suggested that the association between the grade of astrocytoma and the presence of immunohistochemically detectable mos was likely due to the expansion of more aggressive, mos-positive clones of neoplastic cells in the course of malignant tumor progression. This explanation also may apply to ependymomas. However, ependymal neoplasms do not necessarily follow the stereotyped malignant progression of their astroglial counterparts, 17 and overexpression of mos may be present from the outset in a subgroup of ependymal tumors with the potential for relatively aggressive behavior.
In both ependymomas and astrocytomas, 16 mos is detectable exclusively in the cytoplasm, as might be expected of a protein kinase with cytoplasmic activity. On the other hand, mos-positive lung carcinomas often show additional nuclear immunopositivity 14 and aneuploidy, 15 thought to be related to the fact that high levels of mos interfere with assembly of the mitotic spindle in somatic cells. 33 The reason for the variation in subcellular localization of mos between neoplasms of different types is unclear, but this divergence may influence other aspects of the tumor phenotype.
The present study found an inverse relationship between immunopositivity for mos and the recurrence-free interval, although not overall survival. In view of the association ❚Figure 1❚ Survival plots. A, Survival and mos expression in astrocytic tumors (log rank = 1.27; P = .27). B, Recurrence and mos expression in astrocytic tumors (log rank = 3.55; P = .05). Solid line, mos-positive; dotted line, mos-negative. between mos expression and tumor grade, it seems likely that the shorter recurrence-free period in mos-positive tumors simply reflects their more aggressive behavior. In carcinomas of the lung, the presence of immunohistochemically detectable mos was associated with decreased overall survival. 14 The lack of a statistically significant association with overall survival in patients with ependymomas may reflect the modest size of our series. Spinal ependymomas constitute a distinct subtype, many of which have mutations of the NF2 gene on chromosome 22. 34 In the present study, only 1 of 5 spinal ependymomas, all grade II, had detectable mos. The proportion of mos-positive grade II ependymomas in the spinal cord was, therefore, similar to that in the series as a whole (5 of 21 grade II ependymomas). Furthermore, the association between immunopositivity for mos and both the WHO grade and proliferative fraction was significant whether or not spinal ependymomas were included in the analyses.
Overexpression of c-mos in tumors may be of primary pathogenetic importance but also could be a reaction to disturbances of cell cycle regulation. In contrast with the findings of studies of astrocytic gliomas, however, most studies of ependymomas have failed to demonstrate consistent alterations of the cell cycle regulation involving the cyclin D1-Cdk4-pRb-E2F signaling pathway 18 or p53 checkpoint mechanism, [18] [19] [20] [21] [22] [23] 35 whose interrelations with mos and the MAPK pathway might explain the association between elevated mos and neoplastic behavior. 1, 8, 14 On the basis of our current understanding, the accumulation of mos in ependymomas cannot therefore be interpreted simply as a by-product of other, pathogenic molecular events. The similar pattern of mos expression in the genetically distinct astrocytic and ependymal gliomas may underlie a common pathogenetic pathway in these tumors, but this has yet to be defined.
Our findings suggest that mos is involved in the neoplastic transformation of a substantial proportion of ependymal tumors. It remains to be determined whether mos has a causal role in this process and how other components of the MAPK pathway are involved.
